$27.49 Million in Sales Expected for Agios Pharmaceuticals Inc (NASDAQ:AGIO) This Quarter

Wall Street analysts forecast that Agios Pharmaceuticals Inc (NASDAQ:AGIO) will post sales of $27.49 million for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Agios Pharmaceuticals’ earnings. The highest sales estimate is $31.99 million and the lowest is $21.60 million. Agios Pharmaceuticals reported sales of $15.20 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 80.9%. The company is expected to announce its next quarterly earnings results on Thursday, November 7th.

On average, analysts expect that Agios Pharmaceuticals will report full-year sales of $112.85 million for the current year, with estimates ranging from $97.60 million to $122.98 million. For the next fiscal year, analysts anticipate that the firm will report sales of $148.94 million, with estimates ranging from $106.00 million to $188.43 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Agios Pharmaceuticals.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.87) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.70) by ($0.17). The business had revenue of $26.22 million for the quarter, compared to analyst estimates of $27.05 million. Agios Pharmaceuticals had a negative return on equity of 59.89% and a negative net margin of 383.05%. The company’s revenue was down 35.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.19) earnings per share.

Several research analysts have recently issued reports on AGIO shares. BidaskClub raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, August 14th. Piper Jaffray Companies lowered their price objective on Agios Pharmaceuticals from $100.00 to $85.00 and set an “overweight” rating for the company in a research report on Friday, May 3rd. Cowen reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a research report on Friday, May 31st. Zacks Investment Research raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating and set a $46.00 price objective for the company in a research report on Wednesday, August 14th. Finally, Royal Bank of Canada set a $89.00 price objective on Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 2nd. Seven research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Agios Pharmaceuticals currently has an average rating of “Hold” and an average target price of $75.00.

Shares of NASDAQ:AGIO traded up $0.84 on Friday, hitting $43.24. 3,261 shares of the company’s stock were exchanged, compared to its average volume of 582,247. The firm’s 50-day moving average is $45.28 and its 200 day moving average is $53.67. The company has a market capitalization of $2.50 billion, a PE ratio of -7.16 and a beta of 2.19. Agios Pharmaceuticals has a 1-year low of $38.62 and a 1-year high of $85.00. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.91 and a current ratio of 5.96.

Several hedge funds have recently modified their holdings of the company. Wealthstreet Investment Advisors LLC grew its holdings in shares of Agios Pharmaceuticals by 0.9% in the 1st quarter. Wealthstreet Investment Advisors LLC now owns 29,415 shares of the biopharmaceutical company’s stock worth $1,984,000 after acquiring an additional 250 shares during the period. California State Teachers Retirement System grew its holdings in shares of Agios Pharmaceuticals by 0.4% in the 1st quarter. California State Teachers Retirement System now owns 80,018 shares of the biopharmaceutical company’s stock worth $5,396,000 after acquiring an additional 334 shares during the period. US Bancorp DE grew its holdings in shares of Agios Pharmaceuticals by 82.6% in the 2nd quarter. US Bancorp DE now owns 1,010 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 457 shares during the period. Oppenheimer & Co. Inc. grew its holdings in shares of Agios Pharmaceuticals by 0.8% in the 1st quarter. Oppenheimer & Co. Inc. now owns 64,127 shares of the biopharmaceutical company’s stock worth $4,325,000 after acquiring an additional 535 shares during the period. Finally, NumerixS Investment Technologies Inc acquired a new stake in Agios Pharmaceuticals during the 2nd quarter valued at $35,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.

See Also: Market Timing – The Benefits and the Danger

Get a free copy of the Zacks research report on Agios Pharmaceuticals (AGIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.